Tocagen Inc. (NASDAQ: TOCA) today reported preliminary data from the Toca 6 Phase 1 trial of Toca 511 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018April 16, 2018 9:00 AM